530 East 74th StreetNew York, NY 10021
Overview of Dr. Salles
Dr. Gilles Salles is an oncologist based in New York, NY, at Memorial Sloan Kettering Cancer Center, with a subspecialty in hematologic oncology, particularly focused on B-cell lymphomas, follicular lymphoma, and large b-cell lymphoma. He graduated from Université Claude Bernard Lyon in 1989 and has numerous publications in prestigious journals such as New England Journal of Medicine, Lancet, Blood, and Journal of Clinical Oncology. His research contributions include studies on follicular lymphoma, immunotherapies (including bispecific antibodies, CAR T-cell and antibody drug conjugates) as well as molecular characterization of lymphoma. Dr. Salles is actively involved in clinical trials related to lymphoma treatments. He has received several honors, including the T Howard Lee Keynote Lecture in 2023 and the Steven Greenberg Chair in 2021.
Education & Training
Université Claude Bernard LyonClass of 1989
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2025 - 2027
NJ State Medical License 2025 - 2027
NY State Medical License 2021 - 2027
Awards, Honors, & Recognition
- T Howard Lee Keynote Lecture 20th Annual Indy Hematology Review, 2023
- Steven Greenberg Chair MKS, 2021
- Clinicak Keynote Speaker 18th International Ultmann Chicago Lymphoma Symposium, 2021
Clinical Trials
- A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma Start of enrollment: 2022 May 27
Roles: Contact
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. Start of enrollment: 2020 Jun 11
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Start of enrollment: 2023 Sep 18
Publications & Presentations
PubMed
- Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.Allison M Bock, Lei Feng, Ayushi Chauhan, Lorenzo Falchi, Reid Merryman
Blood Advances. 2026-08-25 - Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas.Philipp Berning, Gilles Salles
Expert Opinion on Drug Discovery. 2026-08-01 - 1 citationsMutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.Erel Joffe, Manik Uppal, Serena Zheng, Kurt S Bantilan, Connie Batlevi
Haematologica. 2026-08-01
Press Mentions
DLBCL: Polatuzumab Vedotin Enhances Progression-Free SurvivalDecember 17th, 2021- DLBCL: PFS but No OS Benefit with Polatuzumab-Vedotin Add-OnDecember 17th, 2021
- Incyte : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCLJune 9th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
